|
|
|
|
|
|
|
|
|
|
|
|
|
03.08.26 - 09:24
|
Kyowa Kirin H1 Profit Surges On Higher Revenue (AFX)
|
|
|
TOKYO (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY), a Japanese pharmaceutical company, on Monday reported significantly higher profit for the first half of 2026, driven by growth in revenue, primaril......
|
|
|
22.07.26 - 12:24
|
Kyowa Kirin EMEA′s Crysvita approved by EC for infants with XLH (PBR)
|
|
|
The announcement follows a positive recommendation issued in April 2026 by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). This regulatory action permits
The post Kyowa Kirin EMEA's Crysvita approved by EC for infants with XLH appeared first on Pharmaceutical Business review....
|
|
|
|
|
30.06.26 - 14:33
|
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). These findings, which drew on clinical trial and real-world data, expand the growing body of evidence supporting mogamulizumab use and address critical information gaps where comparative survival data have been limited. The research was funded by Kyowa Kirin Co. Ltd (TSE: 4151)....
|
|
|
29.06.26 - 14:33
|
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced positive results from PROSPER, a real-world observational study of mogamulizumab in adults with mycosis fungoides (MF) or Sézary syndrome (SS). In the study, patients reported clinically meaningful improvements in skin symptoms (itch, flaking, and redness) and body temperature regulation as early as week 4, with improvements in sleep and health-related quality of life (HRQoL) starting at week 12. Improvements were sustained throughout the study period, with additional gains in HRQoL reported through week 48....
|
|
|
|
|
|
|
|
|
|
|
15.05.26 - 11:36
|
Kyowa Kirin secures FDA approval for Crysvita dosing update (PBR)
|
|
|
Affecting adults and children, this rare, progressive, genetic disorder impacts both bone and muscle health due to the body's inability to retain sufficient phosphorus, a mineral essential for
The post Kyowa Kirin secures FDA approval for Crysvita dosing update appeared first on Pharmaceutical Business review....
|
|
|
14.05.26 - 14:33
|
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH (GlobeNewswire EN)
|
|
|
PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved a dosing update to the CRYSVITA® (burosumab-twza) Prescribing Information for adults living with X-linked hypophosphatemia (XLH), a rare, progressive, genetic disease that impacts the bones and muscles in both children and adults. Healthcare providers now have the option to increase the dose and frequency of CRYSVITA for patients whose serum phosphorus is below the normal range after the initial treatment period. These patients may be transitioned to a dosage of 0.5 mg/kg, not to exceed 90 mg, once every 2 weeks. If further dosage increase is needed after 4 weeks of treatment with 0.5 mg/kg every 2 weeks, the dosage can be increased to 1 mg/kg, not to exceed 90 mg, administered every 2 weeks....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
